Lack of ability of ciprofloxacin-rifampin prophylaxis to decrease infection-related morbidity in neutropenic patients given cytotoxic therapy and peripheral blood stem cell transplants

Antimicrob Agents Chemother. 1997 May;41(5):1175-7. doi: 10.1128/AAC.41.5.1175.

Abstract

We compared ciprofloxacin alone with ciprofloxacin plus rifampin (C + R) as a prophylactic antibacterial regimen for 40 patients with solid tumors treated with high-dose chemotherapy and autologous stem cell transplantation support. No differences were found between groups in the time elapsed to the onset of fever, incidence of febrile episodes, amphotericin B use, and length of hospital stay. However, C + R combination prophylaxis significantly reduced the incidence of gram-positive bacteremia (five versus zero episodes) but was associated with a higher incidence of drug-related side effects.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Anti-Bacterial Agents*
  • Anti-Infective Agents / therapeutic use*
  • Antibiotics, Antitubercular / adverse effects
  • Antibiotics, Antitubercular / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Ciprofloxacin / therapeutic use*
  • Drug Therapy, Combination / therapeutic use*
  • Female
  • Fever / etiology
  • Fever / prevention & control
  • Gram-Positive Bacterial Infections / etiology
  • Gram-Positive Bacterial Infections / prevention & control*
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Male
  • Middle Aged
  • Neoplasms / drug therapy*
  • Neoplasms / therapy
  • Neutropenia / chemically induced*
  • Rifampin / adverse effects
  • Rifampin / therapeutic use*

Substances

  • Anti-Bacterial Agents
  • Anti-Infective Agents
  • Antibiotics, Antitubercular
  • Ciprofloxacin
  • Rifampin